Nuvation Bio director granted 76,923 stock options
Nuvation Bio Inc. director Xiangmin Cui corrected a prior insider report to show a grant of 76,923 stock options for Class A common stock received on February 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4/A
Rhea-AI Filing Summary
Nuvation Bio Inc. director Xiangmin Cui corrected a prior insider report to show a grant of 76,923 stock options for Class A common stock received on February 27, 2026. These options have a $5.91 exercise price, expire on February 26, 2036, and vest in 24 monthly installments starting from January 1, 2026.
Insider Trade Summary
Grant/Award: 76,923 shares
Grant/Award
1 txn
Insider
Cui Xiangmin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 76,923 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 76,923 contracts (Direct)
Footnotes (2)
- F1. On March 3, 2026, the reporting person filed a Form 4 which, due to an administrative error, incorrectly reported that the reporting person was awarded 74,813 options to purchase Class A Common Stock on February 27, 2026. In fact, the reporting person was awarded 76,923 options to purchase Class A Common Stock on such date.
- F2. Option vests as to 1/24 of the shares on the one month anniversary of 1/1/2026, monthly thereafter over the following 23 months, subject to Reporting Person's continuous service on each such vesting date
Key Figures
Options granted: 76,923 options
Previously reported options: 74,813 options
Exercise price: $5.91 per share
+3 more
6 metrics
Options granted
76,923 options
Awarded February 27, 2026
Previously reported options
74,813 options
Incorrect amount in earlier Form 4
Exercise price
$5.91 per share
Stock option strike price
Expiration date
February 26, 2036
Option term end
Shares underlying options
76,923 shares
Class A common stock
Total derivative holdings after grant
76,923 options
Total options held following transaction
Key Terms
Stock Option (Right to Buy), Class A Common Stock, Form 4, exercise price, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Class A Common Stock financial
"underlying security title is Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
Form 4 regulatory
"the reporting person filed a Form 4 which, due to an administrative error"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
exercise price financial
"conversion_or_exercise_price of 5.9100 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"Option vests as to 1/24 of the shares on the one month anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Nuvation Bio (NUVB) report in this amended Form 4?
Nuvation Bio reported that director Xiangmin Cui received a grant of 76,923 stock options for Class A common stock on February 27, 2026. The amendment corrects a prior filing that understated the number of options granted as 74,813.
Why was Xiangmin Cui’s Nuvation Bio Form 4 amended?
The Form 4 was amended because a previous filing incorrectly stated that 74,813 options were granted. The corrected filing clarifies that 76,923 stock options for Class A common stock were actually awarded on February 27, 2026.
What are the key terms of Xiangmin Cui’s stock options at Nuvation Bio (NUVB)?
The grant covers 76,923 stock options with an exercise price of $5.91 per share, expiring on February 26, 2036. These options relate to Nuvation Bio’s Class A common stock and were awarded as a compensation grant, not an open-market purchase.
How do the Nuvation Bio (NUVB) options granted to Xiangmin Cui vest?
The options vest over 24 months, with 1/24 of the shares vesting on the one-month anniversary of January 1, 2026. The remaining shares vest monthly over the following 23 months, subject to Xiangmin Cui’s continuous service during each vesting date.
How many Nuvation Bio (NUVB) derivative securities does Xiangmin Cui hold after this grant?
After this grant, Xiangmin Cui holds 76,923 derivative securities in the form of stock options. This total reflects the corrected award amount reported in the amended Form 4 and represents options to buy Nuvation Bio Class A common shares.
Was cash paid in the Nuvation Bio (NUVB) insider transaction for Xiangmin Cui’s options?
No cash changed hands at grant; the options were awarded at a $0.00 grant price as compensation. Any future purchase of shares would occur only if the options are exercised at the $5.91 per share exercise price set in the award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates